Sofinnova secures $750M for 11th fund Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 17 November, 2025

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

presented by Where ded­i­ca­tion de­liv­ers ex­cel­lence in bi­o­log­ics

spotlight Caught between giants: Inside Metsera as Pfizer and Novo battled over obesity's next big prize

news Lilly makes up to $2.6B pact with South Korean biotech Sofinnova secures $750M for 11th fund focused on drugmakers nearing the clinic Nuvalent shares Phase 1/2 data for ALK inhibitor that could battle with Pfizer’s Lorbrena Genmab cans another ADC from ProfoundBio deal in area of J&J's Ambrx buyout

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Wednesday: Bring your rare disease drug to the Japanese market — join PMDA officials to map the path forward. Find out how — get your spot.

endpoints pharma FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study Chinese biotech unveils first-in-class tri-agonist for high lipids, seeks partner CHMP endorses Sanofi diabetes drug, Lilly breast cancer treatment Onshoring and data 'fidelity': What FDA wants from generic drug user fee talks

in case you missed it 1. Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech 2. Despite positive data, Cartesian to pause work in form of lupus in favor of other indications 3. Peer Review Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns 4. Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XI 5. News Briefing Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer program 6. Merck to buy Cidara and its preventive influenza biologic for $9.2B 7. Medicxi, which backed Vicebio and Versanis, closes new €500M biotech fund